semaglutide approval for mash CDSCO Clears Wegovy — India's First GLP-1 for Liver Disease, India's drug regulator CDSCO approved Novo Nordisk's Wegovy (semaglutide 2.4mg) on 17 July 2026 for MASH, based on Semaglutide, a GLP-1R agonist, is

Semaglutide targets the GLP-1 pathway alone, with strong appetite suppression for most patients

To be dispensed by healthcare professionals.

Find out more about Alice's story here

Larger losses typically come later, once a therapeutic maintenance dose is reached

Each 30mL multi-dose vial contains sterile water with 0.9% benzyl alcohol as a bacteriostatic preservative, enabling multiple withdrawals from a single vial while maintaining sterility between uses making it a reliable choice for research environments requiring a contamination-resistant aqueous solution

Lets take a closer look at how Henry Meds performed in each category